FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321934742> ?p ?o ?g. }

• W2321934742 endingPage "215" @default.
• W2321934742 startingPage "209" @default.
• W2321934742 abstract "Cicletanine (CIC), an anti-hypertensive compound with direct vascular and natriuretic actions, is especially effective in salt-sensitive hypertension, in which dysregulation of the sodium pump plays an important pathogenic role, and digitalis-like cardiotonic steroids contribute to increased vascular tone. The purpose of the present study was to investigate whether, and by what mechanisms, cicletanine antagonizes the vasoconstrictor effects of cardiotonic steroids in isolated human arteries.The effects of cicletanine on vascular tone were studied in isolated, endothelium-denuded rings of 2nd-3rd-order branches of human mesenteric arteries pre-contracted with bufodienolide marinobufagenin (MBG), an Na/K-ATPase inhibitor, or endothelin-1 (ET-1). Na/K-ATPase activity was measured in sarcolemmal membranes from the mesenteric artery. Activity of rat brain protein kinase C (PKC) was measured using the PepTag phosphorylation assay.MBG and ET-1 both induced sustained vasoconstriction in human mesenteric artery rings, and cicletanine relaxed rings pre-contracted with either MBG (EC50 = 11 +/- 2 micromol/l) or ET-1 (EC50 = 6.4 +/- 1.1 micromol/l). Although 8-Br-cGMP (100 micromol/l) caused complete vasorelaxation of arterial rings pre-contracted with ET-1, it did not affect the MBG-induced vasoconstriction. An activator of PKC, phorbol diacetate (PDA) (50 nmol/l), attenuated CIC-induced vasorelaxation of mesenteric artery rings pre-contracted with MBG (EC50 > 100 micromol/l), but not rings pre-contracted with ET-1 (EC50 = 6.5 +/- 1.2 micromol/l). In mesenteric artery sarcolemma, 100 nmol/l MBG inhibited the Na/K-ATPase by 68 +/- 5% and cicletanine (100 micromol/l) attenuated this Na/K-ATPase inhibition by 85 +/- 6%. In the PepTag PKC assay, cicletanine produced a concentration-dependent inhibition of rat brain PKC activity (IC50 45 +/- 11 micromol/l). In the presence of 50 nmol/l PDA, 100 micromol/l cicletanine did not antagonize the Na/K-ATPase inhibition by MBG, and did not inhibit the PKC from rat brain.Cicletanine antagonizes vasoconstriction induced by Na/K-ATPase inhibition via a PKC-dependent mechanism that does not involve inhibition of cyclic GMP phosphodiesterase (cGMP-PDE). This mechanism of action may be relevant to the greater potency of cicletanine in salt-sensitive hypertension in which plasma levels of endogenous digitalis-like cardiotonic steroids are elevated. Our findings also suggest that PKC is an important factor for cardiotonic steroid-Na/K-ATPase interactions on the vascular tone, and is therefore a potential target for therapeutic intervention in hypertension." @default.
• W2321934742 created "2016-06-24" @default.
• W2321934742 creator A5000898059 @default.
• W2321934742 creator A5014944442 @default.
• W2321934742 creator A5015556456 @default.
• W2321934742 creator A5060742163 @default.
• W2321934742 creator A5064048331 @default.
• W2321934742 creator A5080812486 @default.
• W2321934742 creator A5083990871 @default.
• W2321934742 date "2000-02-01" @default.
• W2321934742 modified "2023-09-30" @default.
• W2321934742 title "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism" @default.
• W2321934742 cites W1968320638 @default.
• W2321934742 cites W1968382041 @default.
• W2321934742 cites W1973697753 @default.
• W2321934742 cites W1974614964 @default.
• W2321934742 cites W1975532945 @default.
• W2321934742 cites W1976270302 @default.
• W2321934742 cites W1987534461 @default.
• W2321934742 cites W1991370314 @default.
• W2321934742 cites W1993679911 @default.
• W2321934742 cites W1999949811 @default.
• W2321934742 cites W2000612081 @default.
• W2321934742 cites W2025419848 @default.
• W2321934742 cites W2034219543 @default.
• W2321934742 cites W2034373812 @default.
• W2321934742 cites W2046762902 @default.
• W2321934742 cites W2047856300 @default.
• W2321934742 cites W2058547950 @default.
• W2321934742 cites W2063304953 @default.
• W2321934742 cites W2077107089 @default.
• W2321934742 cites W2079717243 @default.
• W2321934742 cites W2079899892 @default.
• W2321934742 cites W2093282657 @default.
• W2321934742 cites W2093378683 @default.
• W2321934742 cites W2093555384 @default.
• W2321934742 cites W2097393837 @default.
• W2321934742 cites W2149584537 @default.
• W2321934742 cites W2156990304 @default.
• W2321934742 cites W2317296223 @default.
• W2321934742 cites W2324734035 @default.
• W2321934742 cites W2325782905 @default.
• W2321934742 cites W2406261766 @default.
• W2321934742 doi "https://doi.org/10.1097/00004872-200018020-00012" @default.
• W2321934742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10694190" @default.
• W2321934742 hasPublicationYear "2000" @default.
• W2321934742 type Work @default.
• W2321934742 sameAs 2321934742 @default.
• W2321934742 citedByCount "16" @default.
• W2321934742 countsByYear W23219347422013 @default.
• W2321934742 countsByYear W23219347422018 @default.
• W2321934742 countsByYear W23219347422020 @default.
• W2321934742 countsByYear W23219347422021 @default.
• W2321934742 countsByYear W23219347422022 @default.
• W2321934742 crossrefType "journal-article" @default.
• W2321934742 hasAuthorship W2321934742A5000898059 @default.
• W2321934742 hasAuthorship W2321934742A5014944442 @default.
• W2321934742 hasAuthorship W2321934742A5015556456 @default.
• W2321934742 hasAuthorship W2321934742A5060742163 @default.
• W2321934742 hasAuthorship W2321934742A5064048331 @default.
• W2321934742 hasAuthorship W2321934742A5080812486 @default.
• W2321934742 hasAuthorship W2321934742A5083990871 @default.
• W2321934742 hasBestOaLocation W23219347422 @default.
• W2321934742 hasConcept C11960822 @default.
• W2321934742 hasConcept C126322002 @default.
• W2321934742 hasConcept C134018914 @default.
• W2321934742 hasConcept C178790620 @default.
• W2321934742 hasConcept C185592680 @default.
• W2321934742 hasConcept C195794163 @default.
• W2321934742 hasConcept C2776820930 @default.
• W2321934742 hasConcept C2779133857 @default.
• W2321934742 hasConcept C2779395532 @default.
• W2321934742 hasConcept C2779961880 @default.
• W2321934742 hasConcept C2780771799 @default.
• W2321934742 hasConcept C2992686903 @default.
• W2321934742 hasConcept C537181965 @default.
• W2321934742 hasConcept C55493867 @default.
• W2321934742 hasConcept C71924100 @default.
• W2321934742 hasConcept C98274493 @default.
• W2321934742 hasConceptScore W2321934742C11960822 @default.
• W2321934742 hasConceptScore W2321934742C126322002 @default.
• W2321934742 hasConceptScore W2321934742C134018914 @default.
• W2321934742 hasConceptScore W2321934742C178790620 @default.
• W2321934742 hasConceptScore W2321934742C185592680 @default.
• W2321934742 hasConceptScore W2321934742C195794163 @default.
• W2321934742 hasConceptScore W2321934742C2776820930 @default.
• W2321934742 hasConceptScore W2321934742C2779133857 @default.
• W2321934742 hasConceptScore W2321934742C2779395532 @default.
• W2321934742 hasConceptScore W2321934742C2779961880 @default.
• W2321934742 hasConceptScore W2321934742C2780771799 @default.
• W2321934742 hasConceptScore W2321934742C2992686903 @default.
• W2321934742 hasConceptScore W2321934742C537181965 @default.
• W2321934742 hasConceptScore W2321934742C55493867 @default.
• W2321934742 hasConceptScore W2321934742C71924100 @default.
• W2321934742 hasConceptScore W2321934742C98274493 @default.
• W2321934742 hasIssue "2" @default.
• W2321934742 hasLocation W23219347421 @default.
• W2321934742 hasLocation W23219347422 @default.

• next